SCHEMBL25883379

SCHEMBL25883379

COCC(F)(F)C(c1ccc(F)cc1)N1C[C@H](C)CC[C@H]1C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 2/20 0.37
▸ TACR1 P25103 3/20 0.32
▸ DPP4 P27487 1/20 0.32
▸ DPP8 Q6V1X1 1/20 0.32
▸ DPP7 Q9UHL4 1/20 0.32
▸ SLC6A3 Q01959 3/20 0.32
▸ DRD3 P35462 2/20 0.32
▸ DRD2 P14416 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ CHRM1 P11229 2/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ HRH1 P35367 1/20 0.31
▸ SLC6A2 P23975 1/20 0.31
▸ SLC6A4 P31645 1/20 0.31
▸ MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25883376 0.85 SIGMAR1 (0.36) SIGMAR1DPP4DPP8DPP7SLC6A3
SCHEMBL21831826 0.83 SIGMAR1 (0.50) SIGMAR1SLC6A3DRD3DRD2KCNH2
SCHEMBL25883366 0.78 SIGMAR1 (0.35) SIGMAR1DPP4DPP8DPP7SLC6A3
SCHEMBL25883375 0.76 MAPT (0.35) SIGMAR1DPP4DPP8DPP7MAPT
SCHEMBL29922641 0.75 TACR1 (0.40) TACR1KCNH2TSHR
SCHEMBL25881977 0.74 SIGMAR1 (0.40) SIGMAR1DPP4DPP8DPP7SLC6A3
SCHEMBL25882219 0.74 SIGMAR1 (0.40) SIGMAR1DPP4DPP8DPP7SLC6A3
SCHEMBL25882229 0.74 SIGMAR1 (0.40) SIGMAR1DPP4DPP8DPP7SLC6A3
SCHEMBL25881984 0.74 SIGMAR1 (0.40) SIGMAR1DPP4DPP8DPP7SLC6A3
SCHEMBL25883264 0.71 SIGMAR1 (0.39) SIGMAR1TACR1SLC6A3DRD3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG SIGMAR1 3220/4885TACR1 2439/4885DPP4 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback